Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery
As Analyst Urges Sawai To Up Domestic Production Capacity
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”
You may also be interested in...
While Sawai’s dominant Japanese business appeared under some strain as the firm started its 2022 financial year, the company appears confident that it is still on track to meet its annual forecast.
Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.